Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fresh blood Clear all
Recruiting Phase 1 Interventional

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

NCT07137494
View directory record Official record
Conditions
Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma
Interventions
MB-CART19.1 Cellular Therapy
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed No phase listed Observational

Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer

NCT00806650
View directory record Official record
Conditions
Kidney Cancer
Interventions
gene expression analysis, protein expression analysis, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method
Genetic · Diagnostic Test · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

NCT00816127
View directory record Official record
Conditions
Liver Cirrhosis, Coagulopathy
Interventions
Desmopressin, blood transfusion
Drug · Biological
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2008 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

NCT06479239
View directory record Official record
Conditions
Pancreas Cancer, Pancreatic Cancer
Interventions
EGFR FPBMC
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strategies to Augment Ketosis: Optimization of Ketone Delivery Strategies

NCT05501366
View directory record Official record
Conditions
Ketosis
Interventions
Ketone Supplement, Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale, Blood Draw, Breath Reading, Heart Rate Variability, CGM/CKM, DXA, Urine Analysis
Dietary Supplement · Behavioral · Biological + 2 more
Lead sponsor
Ohio State University
Other
Eligibility
20 Years to 30 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

NCT04374149
View directory record Official record
Conditions
Cytokine Release Syndrome, COVID19
Interventions
Therapeutic Plasma Exchange, Ruxolitinib
Procedure · Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
12 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 24, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Performance and Reproducibility of the Accelerate PhenoTest™ Blood Culture (BC) Kit With New Antibiotic Wave I Updates

NCT04295915
View directory record Official record
Conditions
Bacteremia
Interventions
Specimens that meet inclusion criteria
Device
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
731 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Tucson, Arizona • Hershey, Pennsylvania • Lewisville, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting No phase listed Observational

Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™

NCT07012291
View directory record Official record
Conditions
Coagulation
Interventions
Whole Blood Clotting Time
Device
Lead sponsor
Perosphere Technologies Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Danbury, Connecticut • Rockville, Maryland • Denville, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

NCT07270978
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
CD33 FPBMC
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed No phase listed Observational

A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors

NCT00745381
View directory record Official record
Conditions
Gastric Cancer, Pancreatic Cancer
Interventions
questionnaire, Blood specimens
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

NCT00948922
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Melphalan, Autologous Stem Cell Transplant, Fludarabine, Allogeneic Stem Cell Transplant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

NCT06158828
View directory record Official record
Conditions
AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
Interventions
Rabbit Anti thymocyte globulin, Busulfan, Fludarabine, Thiotepa, Melphalan, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, memory-like natural killer cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, CliniMACS
Drug · Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets

NCT00074763
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Platelet Transfusion
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Not applicable Interventional Results available

The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity

NCT01903863
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation
Interventions
Fresh frozen plasma
Biological
Lead sponsor
Duke University
Other
Eligibility
1 Day to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

NCT01358734
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions
Azacitidine, Lenalidomide, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

NCT01529502
View directory record Official record
Conditions
Blood Transfusion, Endothelial Physiopathology, Nitric Oxide, Pulmonary Hypertension
Interventions
Red blood Cells auto-transfusion, Inhaled Nitric Oxide (iNO) administration
Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 24, 2026, 4:06 PM EDT
Active, not recruiting Phase 1 Interventional

MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

NCT04555551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Infusion of MCARH109 T cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion

NCT07446647
View directory record Official record
Conditions
Healthy Volunteer Red Blood Cell Labeling Study; Not Disease Focused
Interventions
Biotinylated Red Blood Cells (BioRBC), Irradiated Biotinylated Red Blood Cells (Irradiated BioRBC), 51 Chromium Labeled Red Blood Cells (51Cr RBC), Technetium 99m Labeled Red Blood Cells (99mTc RBC)
Biological
Lead sponsor
Jose Cancelas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine

NCT02597738
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer
Interventions
Fresh tissue biopsy, Blood/Urine Sample Collection
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 99 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US

NCT04010695
View directory record Official record
Conditions
G6PD Deficiency
Interventions
SD Biosensor G6PD Analyzer, Pointe Scientific Test Kit, HemoCue System
Diagnostic Test
Lead sponsor
PATH
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 24, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

NCT00212329
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
T Cell Proliferation and Autoreactivity Assays, Cellular Immunoblot Assays, Tetramer Studies, Cytokine ELISPOT
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Not applicable Interventional

PATCHVALVE: Endobronchial Valves Plus Blood Patch for Persistent Air Leaks

NCT07184528
View directory record Official record
Conditions
Persistent Air Leaks
Interventions
Endobronchial Blood Patch, Spiration Valve System (SVS) Placement
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adverse Effects of RBC Transfusions: A Unifying Hypothesis

NCT00838331
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fresh blood, Aged blood
Biological
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Effect of Physiologic Insulin Administration on Cognition

NCT06424652
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Blood draws, Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test, Resting Metabolic Rate (RMR)
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
65 Years to 75 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 24, 2026, 4:06 PM EDT